Advertisement

Activation of Prodrugs by Antibody-Enzyme Conjugates

  • Peter D. Senter
  • Philip M. Wallace
  • Hakan P. Svensson
  • David E. Kerr
  • Ingegerd Hellstrom
  • Karl Erik Hellstrom
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 303)

Abstract

Monoclonal antibodies (MAbs) against human tumor antigens have been the subject of extensive investigation as carriers of cytotoxic agents to tumor cells. Promising results, both in vitro and in vivo, have been obtained in studies involving immunoconjugates such as MAb-toxins (Vitetta et al., 1987; Blakey et al., 1988), MAb-drugs (Pietersz, 1990; Koppel, 1990), and radiolabeled MAbs (Goldenberg, 1990). Based on these findings, many such conjugates are currently being evaluated in the clinic.

Keywords

H2981 Cell Cytosine Deaminase H2981 Tumor Immunological Specificity Human Tumor Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bagshawe, K.D., 1989, Towards generating cytotoxic agents at cancer sites. Br. J. Cancer, 60:275.PubMedCrossRefGoogle Scholar
  2. Bagshawe, K.D., Springer, C.J., Searle, F., Antoniw P., Sharma, S.K., Melton, R.G., Sherwood, R.F.A., 1988, Cytotoxic agent can be generated selectively at cancer sites, Br. J. Cancer. 58:700.PubMedCrossRefGoogle Scholar
  3. Blakey, D.C., Wawrzynczak, E.J., Wallace, P.M., Thorpe, P.E., 1988, Antibody toxin conjugates: a perspective. Prog. Allergy. 45:50.PubMedGoogle Scholar
  4. Bukhari, M.A., Everett, J.L., and Ross, W.C.J. Glucuronic, Sulphuric and Phosphoric Esters of p-Di-2-chloroethylaminophenol. Biochem. Pharm., 21:963.Google Scholar
  5. Clark, E.A., Shu, G., Ledbetter, J.A., 1985, Role of the bp35 cell surface polypeptide in human B-cell activation. Proc. Natl. Acad. Sci. USA. 82:1766.PubMedCrossRefGoogle Scholar
  6. Goldenberg, D.M., 1990, Cancer Imaging with Radiolabeled Antibodies,Kluwer Academic Publishers, Boston.Google Scholar
  7. Hellstrom, K.E., Yelton, D.E., Fell, H.P., Beaton, D., Gayle, M., MacLean, M., Kahn, M., Hellstrom, I., 1990. Epitope mapping and use of anti-idiotypic antibodies to the L6 monoclonal antibody. Cancer Res., 50: 2449.PubMedGoogle Scholar
  8. Hellstrom, I., Horn, D., Linsley, P., Brown, J.P., Brankovan, V., Hellstrom, K.E., 1986, Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res., 46:3917.PubMedGoogle Scholar
  9. Kerr, D.E., Senter, P.D., Burnett, W.V., Hirschberg, D.L., Hellstrom, I., and Hellstrom, K.E., 1990, Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide, Cancer Immunol. Immunother., 31:202.PubMedCrossRefGoogle Scholar
  10. Koppel, G.A., 1990, Recent advances with monoclonal antibody drug targeting for the treatment of human cancer. Bioconj. Chem., 1:13.CrossRefGoogle Scholar
  11. Pietersz, G.A., 1990, The linkage of cytotoxic drugs to monoclonal antibodies for the treatment of cancer. Bioconj. Chem., 1:89.CrossRefGoogle Scholar
  12. Sands, H., Jones, P.L., Shah, S.A., Plame, D., Vessella, R.C., and Gallagher, B.M., 1988, Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human clouser and renal cell xenografts. Cancer Res., 48:188.PubMedGoogle Scholar
  13. Senter, P.D., Activation of prodrugs by antibody-enzyme conjugates: A new approach to cancer therapy. FASEB. 4:188.Google Scholar
  14. Senter, P.D., Saulnier, M.G., Schreiber, G.J., Hirschberg, D.L., Brown, J.P., Hellstrom, L, Hellstrom, K.E., 1988, Anti-tumor effect of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. USA. 85:4842.PubMedCrossRefGoogle Scholar
  15. Senter, P.D., Schreiber, G.J., Hirschberg, D.L., Ashe, S.A., Hellstrom, K.E., Hellstrom, L, 1990, Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res., 49:5789.Google Scholar
  16. Stanislawski, M., Rousseau, V., Goavec, M., Ito, H., 1989, Immunotoxins containing glucose oxidase and lactoperoxidase with tumoricidal properties: In vitro killing effectiveness in a mouse plasmacytoma cell model Cancer Res., 49:5497.PubMedGoogle Scholar
  17. Thorpe, P.E., 1985, Antibody carriers of cytotoxic agents in cancer therapy: a review, in: “Monoclonal antibodies’ 84: biological and clinical applications,” Editrice Kurtis, Milan.Google Scholar
  18. Vitetta, E.S., Fulton, R.J., May, R.D., Till, M., Uhr, J.W., 1987, Redesigning nature’s poisons to create anti-tumor reagents. Science. 238:1098.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Peter D. Senter
    • 1
  • Philip M. Wallace
    • 1
  • Hakan P. Svensson
    • 1
  • David E. Kerr
    • 1
  • Ingegerd Hellstrom
    • 1
  • Karl Erik Hellstrom
    • 1
  1. 1.OncogenSeattleUSA

Personalised recommendations